Market Overview

Alnylam Pharma Reports Offering of $125M in Stock

Related ALNY
Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia
The Biotech Stock With The Biggest Head Of Steam

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $125 million. All of the shares in the offering are to be sold by Alnylam.

Posted-In: News Offerings

 

Related Articles (ALNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters